(Q37400645)

20 August 2017

Rechallenge with temozolomide in patients with recurrent gliomas (English)

1 reference

20 August 2017

0 references

0 references

6

Ulrich Bogdahn

1 reference

20 August 2017

7

Peter Hau

1 reference

20 August 2017

5

Michael Weller

1 reference

20 August 2017

3

Wolfgang Wick

1 reference

20 August 2017

1

Antje Wick

1 reference

20 August 2017

2

Christina Pascher

1 reference

20 August 2017

Tanja Jauch

4

1 reference

20 August 2017

25 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

256

1 reference

20 August 2017

5

1 reference

20 August 2017

734-741

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-009-5006-9

20 August 2017

0 references

cites work

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-009-5006-9

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

12 December 2020

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

1 reference

12 December 2020

Evaluation of malignant glioma patients during the postirradiation period

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Is protracted low-dose temozolomide feasible in glioma patients?

1 reference

12 December 2020

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

1 reference

12 December 2020

Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

1 reference

12 December 2020

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

Salvage temozolomide for prior temozolomide responders

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

10.1007/S00415-009-5006-9

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19240962